Skip to Content
Merck
All Photos(1)

Documents

C1425000

Chloramphenicol sodium succinate

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

Chloramphenicol succinate sodium salt, Chloramphenicol α-succinate

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Linear Formula:
C15H15Cl2N2O8Na
CAS Number:
982-57-0
Molecular Weight:
445.18
MDL number:
MFCD00079025
UNSPSC Code:
41116107
PubChem Substance ID:
329774883
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

chloramphenicol

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

SMILES string

[Na].O[C@@H]([C@@H](COC(=O)CCC(O)=O)NC(=O)C(Cl)Cl)c1ccc(cc1)N(=O)=O

InChI

1S/C15H16Cl2N2O8.Na.H/c16-14(17)15(24)18-10(7-27-12(22)6-5-11(20)21)13(23)8-1-3-9(4-2-8)19(25)26;;/h1-4,10,13-14,23H,5-7H2,(H,18,24)(H,20,21);;/t10-,13-;;/m1../s1

InChI key

RJOAHMNSYANTPN-OWVUFADGSA-N

Looking for similar products? Visit Product Comparison Guide

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Chloramphenicol sodium succinate EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

related product

Product No.
Description
Pricing

C1200000

Chloramphenicol, European Pharmacopoeia (EP) Reference Standard

C1400000

Chloramphenicol palmitate isomer, European Pharmacopoeia (EP) Reference Standard

C1300000

Chloramphenicol dipalmitate, European Pharmacopoeia (EP) Reference Standard

C1350000

Chloramphenicol disodium disuccinate, European Pharmacopoeia (EP) Reference Standard

PHR1412

Chloramphenicol, Pharmaceutical Secondary Standard; Certified Reference Material

1107004

Chloramphenicol, United States Pharmacopeia (USP) Reference Standard

1107300

Chloramphenicol palmitate, United States Pharmacopeia (USP) Reference Standard

1107401

Chloramphenicol palmitate nonpolymorph A, United States Pharmacopeia (USP) Reference Standard

1107503

Chloramphenicol palmitate polymorph A, United States Pharmacopeia (USP) Reference Standard

BP854

Chloramphenicol, British Pharmacopoeia (BP) Reference Standard

BP1061

Chloramphenicol sodium succinate, British Pharmacopoeia (BP) Reference Standard

BP417

2-Amino-1-(4-nitrophenyl)propane-1,3-diol, British Pharmacopoeia (BP) Reference Standard

Pictograms

Health hazardExclamation mark
GHS08,GHS07

Signal Word

Warning

Hazard Statements

H302,H351

Hazard Classifications

Acute Tox. 4 Oral - Carc. 2

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

M F Festing et al.
Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association, 39(4), 375-383 (2001-04-11)
Much toxicological research continues to be done using genetically undefined "outbred" stocks of mice and rats, although the case for using isogenic strains has been made repeatedly in the literature over a period of more than two decades. Also, very
J A Turton et al.
International journal of experimental pathology, 83(5), 225-238 (2003-03-19)
In man, chloramphenicol (CAP), induces two major haemotoxic effects. First, a reversible, dose-related reticulocytopenia and anaemia developing during treatment. Second, a non-dose-related aplastic anaemia (AA), developing weeks after treatment, is often irreversible and fatal. In previous studies, we developed a
Roberta A Gottlieb et al.
Autophagy, 7(4), 434-435 (2010-12-29)
Interventions that reduce infarct size in animal models have largely failed to improve outcome in patients suffering acute myocardial infarction (MI), or 'heart attack'. Our group recently reported a reduction of infarct size by chloramphenicol treatment in a porcine in
C S Ambekar et al.
European journal of clinical pharmacology, 56(5), 405-409 (2000-09-29)
The metabolism of chloramphenicol succinate (CAPS) by human bone marrow was studied in vitro using 75 marrow samples. Whole marrow samples were incubated with CAPS with or without reduced nicotinamide adenine dinucleotide phosphate for 1, 2 and 3 h at
N J White et al.
Lancet (London, England), 2(8665), 697-701 (1989-09-23)
An open randomised trial was conducted to compare ceftazidime (120 mg/kg/day) with "conventional therapy" (chloramphenicol 100 mg/kg/day, doxycycline 4 mg/kg/day, trimethoprim 10 mg/kg/day, and sulphamethoxazole 50 mg/kg/day) in the treatment of severe melioidosis. A paired restricted sequential trial designed to
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service